中證網訊(記者(zhe) 蔣潔瓊)日(ri)前,赤(chi)天化發布(bu)簡式權(quan)(quan)益變(bian)動報告(gao)書,中國(guo)長城資產管(guan)理股(gu)(gu)(gu)(gu)份有(you)限公(gong)司(si)及其一(yi)致行動人長城國(guo)融投(tou)資管(guan)理有(you)限公(gong)司(si)與公(gong)司(si)持股(gu)(gu)(gu)(gu)5%以上的股(gu)(gu)(gu)(gu)東貴(gui)州赤(chi)天化集(ji)團(tuan)有(you)限公(gong)司(si)簽訂股(gu)(gu)(gu)(gu)權(quan)(quan)轉讓(rang)協議,分別(bie)受(shou)讓(rang)赤(chi)天化集(ji)團(tuan)持有(you)的赤(chi)天化5.43%和5.51%股(gu)(gu)(gu)(gu)份,合計持股(gu)(gu)(gu)(gu)比例約(yue)10.94%,總股(gu)(gu)(gu)(gu)數(shu)達1.9億股(gu)(gu)(gu)(gu),合計金額(e)達10.07億元。
截至報(bao)告(gao)書(shu)簽署日,赤(chi)(chi)天(tian)(tian)化(hua)(hua)集團(tuan)(tuan)共計持(chi)有上市(shi)公司(si)的股(gu)(gu)權比(bi)例為(wei)15.67%。本次協(xie)議轉讓后,赤(chi)(chi)天(tian)(tian)化(hua)(hua)集團(tuan)(tuan)持(chi)股(gu)(gu)比(bi)例下(xia)降(jiang)至4.73%,長(chang)城資產(chan)成為(wei)赤(chi)(chi)天(tian)(tian)化(hua)(hua)第二大(da)股(gu)(gu)東,由(you)于第一(yi)(yi)大(da)股(gu)(gu)東漁陽公司(si)與赤(chi)(chi)天(tian)(tian)化(hua)(hua)集團(tuan)(tuan)為(wei)一(yi)(yi)致(zhi)(zhi)行動人,因此(ci)權益變動未(wei)導致(zhi)(zhi)公司(si)實際控(kong)制人變化(hua)(hua)。
根據赤(chi)天化2月(yue)28日晚(wan)間公告,赤(chi)天化與長(chang)城(cheng)資(zi)產(chan)簽(qian)訂了《戰略合作(zuo)協議(yi)》,長(chang)城(cheng)資(zi)產(chan)將(jiang)協助赤(chi)天化調整存量低效(xiao)資(zi)產(chan),優化企業資(zi)產(chan)負債結(jie)構(gou),同時協助赤(chi)天化加大優質(zhi)資(zi)產(chan)整合力(li)度。
近(jin)來來,公司(si)由化工領域向醫藥大健康轉型的清(qing)晰路徑(jing)。
2016年,赤天化以(yi)發行(xing)股份的方式,購買公司第一大股東及實際控制(zhi)人漁陽(yang)公司持有(you)的圣濟(ji)堂(tang)100%股權(quan),同時募集配(pei)套資金19.87億元,其中(zhong)7.7億元用(yong)于貴州觀(guan)山湖腫瘤醫院建設(she)項目(mu)(mu),2.6億元用(yong)于貴州圣濟(ji)堂(tang)糖尿病醫院建設(she)項目(mu)(mu)。
據(ju)了解,通過這次(ci)重(zhong)組,赤天化開始進軍醫(yi)(yi)療與制(zhi)藥(yao)(yao)領(ling)域,主營業(ye)務亦由(you)單一(yi)化工轉(zhuan)(zhuan)變為(wei)“化工+醫(yi)(yi)藥(yao)(yao)”雙輪驅(qu)動。進入2018年(nian),赤天化向醫(yi)(yi)藥(yao)(yao)大健康產業(ye)轉(zhuan)(zhuan)型的步伐加快,收購中(zhong)觀生(sheng)物(wu)80%的股權,向干細胞(bao)和基因(yin)藥(yao)(yao)品等高(gao)端醫(yi)(yi)療領(ling)域布局,還與中(zhong)鈺資(zi)本簽訂戰略合作協議,約定由(you)中(zhong)鈺資(zi)本推薦生(sheng)物(wu)制(zhi)藥(yao)(yao)、干細胞(bao)治療等醫(yi)(yi)藥(yao)(yao)制(zhi)造領(ling)域標的,并協助完成最終收購。
業(ye)(ye)(ye)內人(ren)士分析,2016年(nian),重組時所做的(de)(de)(de)三年(nian)內不(bu)會(hui)剝(bo)離化工(gong)主業(ye)(ye)(ye)承諾即將于明年(nian)到期(qi)。由于2017年(nian)以(yi)來(lai)(lai)尿素(su)、甲(jia)醇行情轉(zhuan)好(hao),對于調(diao)整(zheng)優化公(gong)司資產(chan)結構十分有(you)利。此時引入擁有(you)豐富并(bing)購重組經驗的(de)(de)(de)長(chang)城(cheng)資產(chan),將為公(gong)司業(ye)(ye)(ye)務(wu)(wu)(wu)轉(zhuan)型(xing)升(sheng)級(ji)增添一(yi)枚重要(yao)砝碼。長(chang)城(cheng)資產(chan)自成(cheng)立以(yi)來(lai)(lai),圍繞優化社會(hui)資源配置、服(fu)(fu)(fu)務(wu)(wu)(wu)實體(ti)經濟發(fa)展(zhan),成(cheng)功運作過(guo)一(yi)大批以(yi)“ST超日”、“中(zhong)國鐵物”、“廣(guang)譽遠”為代表的(de)(de)(de)重大并(bing)購重組案例(li),在推動(dong)企(qi)業(ye)(ye)(ye)要(yao)素(su)整(zheng)合(he)、促(cu)進經濟結構調(diao)整(zheng)和(he)轉(zhuan)型(xing)升(sheng)級(ji)方面(mian)具有(you)獨特的(de)(de)(de)專業(ye)(ye)(ye)優勢。不(bu)僅如此,具有(you)金(jin)(jin)融(rong)(rong)(rong)“全(quan)牌照”的(de)(de)(de)長(chang)城(cheng)資產(chan)還(huan)能為企(qi)業(ye)(ye)(ye)提供一(yi)攬子的(de)(de)(de)全(quan)生命周(zhou)期(qi)和(he)全(quan)產(chan)業(ye)(ye)(ye)鏈的(de)(de)(de)綜(zong)合(he)金(jin)(jin)融(rong)(rong)(rong)服(fu)(fu)(fu)務(wu)(wu)(wu),后(hou)續有(you)望(wang)根(gen)據(ju)企(qi)業(ye)(ye)(ye)在不(bu)同發(fa)展(zhan)階段的(de)(de)(de)金(jin)(jin)融(rong)(rong)(rong)服(fu)(fu)(fu)務(wu)(wu)(wu)需(xu)求,向公(gong)司提供包括銀行貸款(kuan)、證(zheng)券、金(jin)(jin)融(rong)(rong)(rong)租(zu)賃、信托、基金(jin)(jin)和(he)保(bao)險(xian)等在內的(de)(de)(de)綜(zong)合(he)金(jin)(jin)融(rong)(rong)(rong)服(fu)(fu)(fu)務(wu)(wu)(wu)產(chan)品(pin),以(yi)多元化的(de)(de)(de)金(jin)(jin)融(rong)(rong)(rong)服(fu)(fu)(fu)務(wu)(wu)(wu)手段不(bu)斷激發(fa)企(qi)業(ye)(ye)(ye)的(de)(de)(de)內生發(fa)展(zhan)動(dong)力和(he)創新活力,持續提升(sheng)企(qi)業(ye)(ye)(ye)內涵(han)價值,促(cu)進企(qi)業(ye)(ye)(ye)可持續發(fa)展(zhan)。
中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)聲明(ming)(ming):凡本網(wang)(wang)(wang)注(zhu)明(ming)(ming)“來源:中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券報(bao)(bao)(bao)·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)”的(de)所有作(zuo)品(pin),版權(quan)(quan)均(jun)屬于中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券報(bao)(bao)(bao)、中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)。中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券報(bao)(bao)(bao)·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)與(yu)作(zuo)品(pin)作(zuo)者(zhe)聯合聲明(ming)(ming),任何組織未經中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券報(bao)(bao)(bao)、中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)以及作(zuo)者(zhe)書面(mian)授權(quan)(quan)不(bu)得(de)轉載(zai)、摘編或(huo)利用(yong)其它方式使用(yong)上述(shu)作(zuo)品(pin)。凡本網(wang)(wang)(wang)注(zhu)明(ming)(ming)來源非中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券報(bao)(bao)(bao)·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)的(de)作(zuo)品(pin),均(jun)轉載(zai)自其它媒(mei)體,轉載(zai)目的(de)在于更(geng)好服務(wu)讀(du)者(zhe)、傳遞信(xin)息之需,并不(bu)代表(biao)本網(wang)(wang)(wang)贊(zan)同其觀點,本網(wang)(wang)(wang)亦(yi)不(bu)對其真實性(xing)負責,持異議者(zhe)應(ying)與(yu)原出處(chu)單位主張權(quan)(quan)利。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved
中國(guo)證券報社(she)版(ban)權所(suo)有(you),未(wei)經書面授權不得復制或建立鏡像
經營(ying)許可(ke)證編號:京(jing)B2-20180749 京(jing)公(gong)網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved